contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment CompanyTagList on Company {
  pageUrl
  name
  viewerIsFollowing
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    ...CompanyTagList
    id
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls {
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      defaultInstrument {
        isin
        id
      }
      id
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    id
    name
    viewerIsFollowing
    defaultInstrument {
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


a-new-publication-using-attana-technology-from-national-university-of-singapore-examining-the-neutralization-capacity-of-human-igg-antibodies-agsinst-different-mutations-of-the-sars-cov-2

__typename

title

isPremium

lang

htmlBody

companies

createdAt

publishers

authors

reactionGroups

pageUrl

alternatePageUrls

imgUrl

description

Attana conducts research and development of pharmaceuticals. The company specialises in vitro characterization of molecular interactions, which is used for analysis in the development of new pharmaceuticals. The company's patented solutions are mainly used in the study of different binding properties and macrostructures in cells, proteins, viruses, and bacteria. Operations are found mainly within the Nordic countries and Europe. The company was established in 2002 is based in Stockholm.

Attana

During the pandemic it has been observed that individuals react very differently to be infected by the virus and to the vaccination. A few individuals obtain very strong protection against the...

<div class="abstract">During the pandemic it has been observed that individuals react very differently to be infected by the virus and to the vaccination. A few individuals obtain very strong protection against the wild type (the original Wuhan) and the mutated variants, whereas others obtain less good protection. This paper in Nature Communications&nbsp;(<a href="https://www.nature.com/articles/s41467-023-42408-x">https://www.nature.com/articles/s41467-023-42408-x</a>) focus on characterizing the neutralization capacity (protection) of antibodies from convalescent COVID-19 individuals against SARS-CoV-2 virus. Using Attana technology, kinetic characterization of the antibody-spike interaction reveals that the antibodies with the best kinetics properties are the same ones that provides the that the strongest neutralizing capacity. For Attana these results are yet another independent research publication with results that supports our concept of immunity profiles where kinetic interaction properties are used to determine how well protection an individual has to a given pathogen.</div>The uniqueness of this paper is the combination of many different technologies and that the studies have been performed at experimentally challenging but physiologically more relevant conditions than previously published results. For instance, have the effect of glycosylation of the spike mutations and the importance of the dynamics of the interaction been included. Overall, this resulted in that the antibodies from convalescent individuals could be divided into weak, moderate, and strong neutralizers.Attana QCM technology has been applied to study the interaction kinetics of the different antibodies.&nbsp; High affinity binding in the sub-nM range with slow dissociation rates were observed. The association-dissociation kinetics clearly indicate stable binding of the antibodies to the Spike trimer. In the neutralization experiments the highest neutralization was observed for the two antibodies CoVA2-39 and 5A6. These two antibodies have the fastest association rate, being 1.25*106mol/s and 1.18*106mol/s respectively.Association rates in the magnitude of 106mol/s has in several previous studies using Attana technology been observed to correlate with strong neutralization, e.g. for SARS-CoV-2, dengue, hepatis B, tetanus, and tuberculosis. In correlation with the dissociation rate, this is used as criteria's in Attana's immunity profiles, where kinetic interaction properties are used to determine how well protection an individual has to a given pathogen. Consequently, this study forms a good reference for the application of Attana technology and kinetic characterization as a mean for determine neutralizing capacity.[En bild som visar text, diagram, Teckensnitt, linjeAutomatiskt genererad beskrivning]Attana QCM kinetic evaluation of the interactions between Spike and SARS CoV-2 antibodies

A new publication using Attana Technology from National University of Singapore examining the neutralization capacity of human IgG antibodies agsinst different mutations of the SARS-CoV-2

Stay up to date with our newsletter